Abstract

<p>Fig. S1. Importance of mutant KRAS status for cellular and clinical radioresistance. Fig. S2. Characterization of the CSC-like features of KRAS mutant NSCLC cells. Fig. S3. Pathway analysis of differentially expressed genes in KRAS mutant vs wild-type NCI-H1703 cells. Fig. S4. Factors influencing the radioresistance of NSCLC cell lines with mutant KRAS. Fig. S5. Role of SPP1/osteopontin expression in KRAS mutant and wild-type NSCLC cell lines and tumors. Fig. S6. Characterization of MLCC alterations in KRAS mutant NSCLC. Fig. S7. BIM regulation and importance of p53/p16 alterations in KRASmut NSCLC.</p>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.